Abstract
Fever is frequently observed in conjunction with interleukin-2 (IL-2)-based immunotherapy. Traditionally, fever has been regarded as an undesirable side effect and treated with fever-lowering drugs. However, new insights in tumor immunology suggest that elevated temperature may facilitate a more effective antitumor immune response. The purpose of this retrospective study was to examine the potential role of the IL-2-induced fever in melanoma patients treated with or without paracetamol in two consecutive cohorts. One hundred and seventy-nine patients with metastatic melanoma treated with a modified decrescendo regimen of IL-2 and Interferon (IFN) between 2004 and 2010 were retrospectively studied. 87 patients treated before 2007 received paracetamol as part of the treatment schedule, and 92 patients treated after 2007 did not receive paracetamol routinely. Body temperature was analyzed as dichotomized and continuous variables and correlated to objective tumor response and overall survival using logistic regression and Cox proportional hazard analysis. Patients experiencing peak temperature of ≥39.5 °C had a median OS of 15.2 months compared to 8.7 months among patients with lower temperatures (P = 0.01). In the multivariate analysis, peak temperature of ≥39.5 °C (HR 0.53; P = 0.026) and high mean temperature (HR 0.56; P = 0.004) were independent prognostic factors for improved survival. We suggest high fever as a biomarker for improved survival in melanoma patients treated with IL-2/IFN. The routine use of fever-reducing drugs during immunotherapy can therefore be questioned. More studies are needed to evaluate the role of fever and the use of antipyretics during cytokine-based immunotherapy.
Similar content being viewed by others
Abbreviations
- AUC:
-
Area under the curve
- CI:
-
Confidence interval
- CR:
-
Complete response
- CT:
-
Computed tomography
- DC:
-
Dendritic cells
- HR:
-
Hazard ratio
- IFN:
-
Interferon alpha
- IL-2:
-
Interleukin-2
- LDH:
-
Lactate dehydrogenase
- MU:
-
Million units
- NK:
-
Natural killer cells
- NSAIDs:
-
Non-steroidal anti-inflammatory drugs
- OS:
-
Overall survival
- PR:
-
Partial response
- PS:
-
WHO performance status
- RECIST:
-
Response criteria for solid tumors
- SD:
-
Stable disease
References
Diepgen TL, Mahler V (2002) The epidemiology of skin cancer. Br J Dermatol 146(Suppl 61):1–6
Volkovova K, Bilanicova D, Bartonova A, Letasiova S, Dusinska M (2012) Associations between environmental factors and incidence of cutaneous melanoma. Review. Environ Health 11(Suppl 1):S12. doi:10.1186/1476-069x-11-s1-s12
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi:10.1056/NEJMoa1003466
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516. doi:10.1056/NEJMoa1103782
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. doi:10.1056/NEJMoa1200690
Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23(6):488–496
Antony GK, Dudek AZ (2010) Interleukin 2 in cancer therapy. Curr Med Chem 17(29):3297–3302
Hasday JD, Fairchild KD, Shanholtz C (2000) The role of fever in the infected host. Microbes infect 2(15):1891–1904
Hobohm U (2005) Fever therapy revisited. Br J Cancer 92(3):421–425. doi:10.1038/sj.bjc.6602386
Kleef R, Jonas WB, Knogler W, Stenzinger W (2001) Fever, cancer incidence and spontaneous remissions. Neuroimmunomodulation 9(2):55–64. doi:10.1159/000049008
Kluger MJ (1986) Is fever beneficial? Yale J Biol Med 59(2):89–95
Roberts NJ Jr (1991) Impact of temperature elevation on immunologic defenses. Rev Infect Dis 13(3):462–472
Basu S, Srivastava PK (2003) Fever-like temperature induces maturation of dendritic cells through induction of hsp90. Int Immunol 15(9):1053–1061
Hobohm U, Stanford JL, Grange JM (2008) Pathogen-associated molecular pattern in cancer immunotherapy. Crit Rev Immunol 28(2):95–107
Mace TA, Zhong L, Kokolus KM, Repasky EA (2012) Effector CD8+ T cell IFN-gamma production and cytotoxicity are enhanced by mild hyperthermia. Int J Hyperth 28(1):9–18. doi:10.3109/02656736.2011.616182
Ostberg JR, Repasky EA (2006) Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function. Cancer Immunol Immunother 55(3):292–298. doi:10.1007/s00262-005-0689-y
Jozwiak-Bebenista M, Nowak JZ (2014) Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm 71(1):11–23
Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U (2007) Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 25(12):1562–1569. doi:10.1200/jco.2006.09.0274
Wisco OJ, Sober AJ (2012) Prognostic factors for melanoma. Dermatol Clin 30(3):469–485. doi:10.1016/j.det.2012.04.008
Mier JW, Vachino G, Klempner MS, Aronson FR, Noring R, Smith S, Brandon EP, Laird W, Atkins MB (1990) Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 76(10):1933–1940
Mier JW, Vachino G, van der Meer JW, Numerof RP, Adams S, Cannon JG, Bernheim HA, Atkins MB, Parkinson DR, Dinarello CA (1988) Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 8(6):426–436
Roberts NJ, Zhou S, Diaz LA Jr, Holdhoff M (2011) Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2(10):739–751
Hobohm U (2001) Fever and cancer in perspective. Cancer Immunol Immunother 50(8):391–396
Eberlein TJ, Schoof DD, Michie HR, Massaro AF, Burger U, Wilmore DW, Wilson RE (1989) Ibuprofen causes reduced toxic effects of interleukin 2 administration in patients with metastatic cancer. Arch Surg 124(5):542–547
Sosman JA, Kohler PC, Hank JA, Moore KH, Bechhofer R, Storer B, Sondel PM (1988) Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 80(18):1451–1461
Hoption Cann SA, van Netten JP, van Netten C (2003) Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 79(938):672–680
Nauts HC, Fowler GA, Bogatko FH (1953) A review of the influence of bacterial infection and of bacterial products (Coley’s toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley’s mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl 276:1–103
Hoption Cann SA, van Netten JP, van Netten C, Glover DW (2002) Spontaneous regression: a hidden treasure buried in time. Med Hypotheses 58(2):115–119. doi:10.1054/mehy.2001.1469
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Køstner, A.H., Ellegaard, MB.B., Christensen, I.J. et al. Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma. Cancer Immunol Immunother 64, 349–355 (2015). https://doi.org/10.1007/s00262-014-1637-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-014-1637-5